Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Citi
Daiichi Sankyo
Cantor Fitzgerald
Chinese Patent Office
Baxter
Queensland Health
Mallinckrodt
Chubb

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,737,489

« Back to Dashboard

Title:Controlled release and taste masking oral pharmaceutical composition
Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
Inventor(s): Villa; Roberto (Lecco, IT), Pedrani; Massimo (Gignese, IT), Ajani; Mauro (Milan, IT), Fossati; Lorenzo (Milan, IT)
Assignee: COSMO TECHNOLOGIES LIMITED (Dublin, IE)
Filing Date:Dec 05, 2016
Application Number:15/368,911
Claims:1. A method of treating a human subject with ulcerative colitis, comprising administering to said human subject an oral pharmaceutical composition in the form of a tablet consisting essentially of: (a) a tablet core comprising granules, said granules comprising 9 mg of budesonide, at least one lipophilic or inert matrix, and at least one amphiphilic matrix, wherein said granules are dispersed in a composition comprising at least one hydrophilic matrix; and (b) a tablet coating comprising a gastro-resistant film, wherein said gastro-resistant film comprises a plasticizer and at least one methacrylic acid copolymer; and wherein said oral pharmaceutical composition provides a C.sub.max of said budesonide in said human subject of about 1.35.+-.0.96 ng/mL following said administration of said oral pharmaceutical composition to said human subject.

2. The method according to claim 1, wherein said oral pharmaceutical composition further provides a T.sub.max of said budesonide in said human subject of about 13.3.+-.5.9 hours following administration of said oral pharmaceutical composition to said human subject.

3. The method according to claim 1, wherein said oral pharmaceutical composition further provides an AUC.sub.0-infinity of said budesonide in said human subject of about 16.43.+-.10.52 (ng)(hr)/mL following said administration of said oral pharmaceutical composition to said human subject.

4. The method according to claim 1, wherein said oral pharmaceutical composition further provides an AUC.sub.0-t of said budesonide in said human subject of about 13.56.+-.7.82 (ng)(hr)/mL in 36 hours following said administration of said oral pharmaceutical composition to said human subject.

5. The method according to claim 1, wherein said gastro-resistant film in said oral pharmaceutical composition comprises methacrylic acid copolymer type A.

6. The method according to claim 1, wherein said oral pharmaceutical composition further provides: (1) a T.sub.max of said budesonide in said human subject of about 13.3.+-.5.9 hours; and (2) an AUC.sub.0-infinity of said budesonide in said human subject of about 16.43.+-.10.52 (ng)(hr)/mL, following said administration of said oral pharmaceutical composition to said human subject.

7. A method of treating a human subject with ulcerative colitis, comprising administering to said human subject an oral pharmaceutical composition in the form of a tablet consisting essentially of: (a) a tablet core comprising granules, said granules comprising 9 mg of budesonide, at least one lipophilic or inert matrix, and at least one amphiphilic matrix, wherein said granules are dispersed in a composition comprising at least one hydrophilic matrix; and (b) a tablet coating comprising a gastro-resistant film, wherein said gastro-resistant film comprises a plasticizer and at least one methacrylic acid copolymer; and wherein said oral pharmaceutical composition provides a C.sub.max of said budesonide in said human subject of from about 0.49 ng/mL to about 4.23 ng/mL following said administration of said oral pharmaceutical composition to said human subject.

8. The method according to claim 7, wherein said oral pharmaceutical composition further provides a T.sub.max of said budesonide in said human subject of about 13.3.+-.5.9 hours following administration of said oral pharmaceutical composition to said human subject.

9. The method according to claim 7, wherein said oral pharmaceutical composition further provides an AUC.sub.0-infinity of said budesonide in said human subject of about 16.43.+-.10.52 (ng)(hr)/mL following said administration of said oral pharmaceutical composition to said human subject.

10. The method according to claim 7, wherein said oral pharmaceutical composition further provides an AUC.sub.0-t of said budesonide in said human subject of about 13.56.+-.7.82 (ng)(hr)/mL in 36 hours following said administration of said oral pharmaceutical composition to said human subject.

11. The method according to claim 7, wherein in said oral pharmaceutical composition said gastro-resistant film comprises methacrylic acid copolymer type A.

12. The method according to claim 7, wherein said oral pharmaceutical composition further provides: (1) a T.sub.max of said budesonide in said human subject of about 13.3.+-.5.9 hours; and (2) an AUC.sub.0-infinity of said budesonide in said human subject of about 16.43.+-.10.52 (ng)(hr)/mL, following said administration of said oral pharmaceutical composition to said human subject.

13. A method of treating a human subject with ulcerative colitis, comprising administering to said human subject an oral pharmaceutical composition in the form of a tablet consisting essentially of: (a) a tablet core comprising granules, said granules comprising 9 mg of budesonide, stearic acid, and lecithin, wherein said granules are dispersed in a composition comprising hydroxypropyl cellulose; and (b) a tablet coating comprising a gastro-resistant film, wherein said gastro-resistant film comprises a plasticizer and at least methacrylic acid copolymer, and wherein said oral pharmaceutical composition provides a C.sub.max of said budesonide in said human subject of about 1.35.+-.0.96 ng/mL following said administration of said oral pharmaceutical composition to said human subject.

14. The method according to claim 13, wherein said oral pharmaceutical composition further provides a T.sub.max of said budesonide in said human subject of about 13.3.+-.5.9 hours following administration of said oral pharmaceutical composition to said human subject.

15. The method according to claim 13, wherein said oral pharmaceutical composition further provides an AUC.sub.0-infinity of said budesonide in said human subject of about 16.43.+-.10.52 (ng)(hr)/mL following said administration of said oral pharmaceutical composition to said human subject.

16. The method according to claim 13, wherein said oral pharmaceutical composition further provides an AUC.sub.0-t of said budesonide in said human subject of about 13.56.+-.7.82 (ng)(hr)/mL in 36 hours following said administration of said oral pharmaceutical composition to said human subject.

17. The method according to claim 13, wherein in said oral pharmaceutical composition said gastro-resistant film comprises methacrylic acid copolymer type A.

18. The method according to claim 13, wherein said oral pharmaceutical composition further provides: (1) a T.sub.max of said budesonide in said human subject of about 13.3.+-.5.9 hours; and (2) an AUC.sub.0-infinity of said budesonide in said human subject of about 16.43.+-.10.52 (ng)(hr)/mL, following said administration of said oral pharmaceutical composition to said human subject.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
QuintilesIMS
Baxter
Federal Trade Commission
McKesson
Cerilliant
Teva
Moodys
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.